HEALTH AND ECONOMIC BURDEN OF INTERSTITIAL LUNG DISEASES
RESEARCHER PROFILE (Filmed April 2024)
Dr Ingrid Cox
Postdoctoral Research Fellow
Menzies Institute for Medical Research
University of Tasmania
Dr Ingrid Cox is a Postdoctoral Research Fellow at the Menzies Institute for Medical Research, University of Tasmania. She is a physician and health economist by training and has extensive experience working in healthcare, including in clinical practice, public health, health policy and health planning, and has worked with regional governmental agencies in the Caribbean and international development partners working in health.
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
Dr Cos completed her PhD in 2022 and since then has been the recipient of two Fellowships, the first the Menzies Postdoctoral Fellowship and the second a Fellowship with Lung Foundation Australia.
Currently Dr Cox’s research work spans several areas including her continued work on IPF and other interstitial lung diseases on several national projects, health services research including some work with the Royal Flying Doctor Service, prostate cancer research and her current lung cancer research funded by the major project grant of the Royal Hobart Hospital Research Foundation.
Dr Cox holds executive committee positions on the Australian Health Economics Society, the Professional Society or Health Economics and Outcomes Research both nationally and internationally, is currently the President of the Thoracic Society of Australia and New Zealand Tasmanian Branch and Chair of the Lung Cancer Special Interest Group.
Source: Supplied, Centre Of Research Excellence In Pulmonary Fibrosis
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Biological interactions of extracellular vesicles
Raluca Ghebosu graduated from the University of Queensland with a Bachelor of Arts/Bachelor of Science with majors in Japanese and Biomedical Science (2018-2021). She then completed her Bachelor of Science (Honours) with the School of Biomedical Sciences at the University of Queensland in 2022, before pursuing a PhD with A/Prof. Joy Wolfram at the Australian Institute for Bioengineering and Nanotechnology.
-
Professor Christoph Hagemeyer
RESEARCH IN NANOBIOTECHNOLOGY
@ MONASH UNIVERSITY
VICTORIA, AUSTRALIA
